Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
How precise cancer care is
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Cancers
Advanced-stage classical Hodgkin lymphoma (stage III to IV)
Data

Cancers·Advanced-stage classical Hodgkin lymphoma (stage III to IV)

DataAdvanced-stage classical Hodgkin lymphoma (stage III to IV)

Back to the Advanced-stage classical Hodgkin lymphoma hub →103 connected records · 1 note

Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.

Overview Types and stages Symptoms and diagnosis Treatment Trials and papers Biology and targets Countries and centres Decisions and support Pipeline and open problems Data

Data

Related pages

103

Direct links plus the targets, companies, and technologies of this cancer's products.

Similar pages

Cancer
Rosai-Dorfman-Destombes disease
Shares FDG PET, IMRT / IGRT (modern external beam) and the tags subtype-page, haematologic.
Cancer
Erdheim-Chester disease
Shares FDG PET and the tags subtype-page, haematologic.
Cancer
Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia)
Shares the tags subtype-page, haematologic.
Cancer
Indolent and smouldering systemic mastocytosis
Shares the tags subtype-page, haematologic.
Cancer
Primary mediastinal (thymic) large B-cell lymphoma
Shares Fertility preservation before lymphoma treatment: a decision with a deadline in days, Fertility before lymphoma treatment: what to ask for, and when, ctDNA monitoring in lymphoma (PhasED-seq, clonoSEQ), PET-adapted (response-adapted) therapy and the tag subtype-page.
Cancer
Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma)
Shares Central venous access (port, PICC line), Stem cell transplant in lymphoma: what it is still for, CD30, Exercise during chemotherapy and radiotherapy and the tags subtype-page, haematologic.
Cancer
Nodal marginal zone lymphoma
Shares Hypogammaglobulinaemia and infection risk after B-cell therapies, Central venous access (port, PICC line), Radiotherapy in lymphoma: involved-site fields, 24 Gy, 4 Gy and total skin electron therapy, Exercise during chemotherapy and radiotherapy and the tags subtype-page, haematologic.
Cancer
Waldenström macroglobulinaemia
Shares A clinical trial or standard treatment in lymphoma, Fatigue after lymphoma treatment, and why it is a symptom to report, Hypogammaglobulinaemia and infection risk after B-cell therapies, Central venous access (port, PICC line) and the tag haematologic.

technologies

Allogeneic stem cell transplantation Antibody-drug conjugate (ADC)Antiemetics for chemotherapy-induced nausea and vomiting Autologous stem cell transplant (high-dose therapy)CAR-T cell therapy Cardio-oncology Cognitive behavioural therapy for fatigue and distress ctDNA monitoring in lymphoma (PhasED-seq, clonoSEQ)Cytotoxic chemotherapy Early integrated palliative care Electrochemotherapy Exercise during chemotherapy and radiotherapy FDG PET Financial toxicity and financial navigation Growth factors: G-CSF and febrile neutropenia prevention Immune checkpoint inhibitors IMRT / IGRT (modern external beam)Multidisciplinary tumour boards Nutrition support and cachexia management Oncofertility and fertility preservation Peer support and support groups PET-adapted (response-adapted) therapy PET/CT Prehabilitation before cancer surgery Psycho-oncology and distress screening Survivorship care and late-effects surveillance Topoisomerase-I inhibitors (and ADC payloads)

targets

CD30 Glucocorticoid receptor (NR3C1)KMT2A (MLL) rearrangement PD-1 PD-L1

drugs

ApprovedGlycopeptide antibiotic (DNA-cleaving)

Bleomycin · Blenoxane

ApprovedADC

Brentuximab vedotin · Adcetris

ApprovedAlkylating agent (oxazaphosphorine prodrug)

Cyclophosphamide · Cytoxan / Endoxan

ApprovedAlkylating agent (triazene)

Dacarbazine · DTIC-Dome (historic)

ApprovedGlucocorticoid

Dexamethasone · Decadron (historic) / Hemady / Neofordex

ApprovedCytotoxic chemotherapy (anthracycline)

Doxorubicin · Adriamycin

ApprovedTopoisomerase II inhibitor (podophyllotoxin derivative)

Etoposide · VePesid / Etopophos / Toposar

ApprovedMonoclonal antibody (anti-PD-1)

Nivolumab · Opdivo / Opdivo Qvantig (SC)

ApprovedMonoclonal antibody (anti-PD-1)

Pembrolizumab · Keytruda / Keytruda Qlex (SC)

ApprovedAlkylating-like methylhydrazine derivative

Procarbazine · Matulane

ApprovedVinca alkaloid (microtubule inhibitor)

Vinblastine · Velban

ApprovedVinca alkaloid (microtubule inhibitor)

Vincristine · Oncovin / Marqibo

companies

Bristol Myers Squibb Children's Oncology Group (COG)Eli Lilly (incl. Loxo)German Breast Group (GBG)Leadiant Biosciences Merck & Co. (MSD)Ono Pharmaceutical Pfizer (incl. Seagen)Takeda

terms

A clinical trial or standard treatment in lymphoma ABVD, BEACOPP and BrECADD (Hodgkin lymphoma regimens)After Hodgkin lymphoma: the late effects, and the screening that follows them British and American lymphoma practice: where they differ, and why Cancer-related fatigue (tiredness)Cardiotoxicity (LVEF decline, cardiomyopathy)Central venous access (port, PICC line)Deauville five-point scale Deauville score and PET-adapted therapy Escalated chemotherapy or ABVD in advanced Hodgkin lymphoma: more cures, more late harm, and what the interim scan changed Fatigue after lymphoma treatment, and why it is a symptom to report Febrile neutropenia Fertility before lymphoma treatment: what to ask for, and when Fertility preservation before lymphoma treatment: a decision with a deadline in days Financial toxicity Hypogammaglobulinaemia and infection risk after B-cell therapies Late effects and survivorship toxicity Late effects of Hodgkin lymphoma treatment, and the follow-up that answers them Lugano classification / Ann Arbor staging Neutropenia Performance status (ECOG, Karnofsky)Quality of life Radiotherapy in lymphoma: involved-site fields, 24 Gy, 4 Gy and total skin electron therapy Reed-Sternberg cell Secondary malignancy (therapy-related cancer)Stem cell transplant in lymphoma: what it is still for The lymphoma regimen alphabet: R-CHOP, pola-R-CHP, DA-EPOCH-R, ABVD, BEACOPP and the rest What the NHS in England funds for lymphoma, appraisal by appraisal

trials

A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma AHL2011 AHOD1331 ECHELON-1 GHSG HD18 GHSG HD21 RATHL SWOG S1826

pairings

Caution: bleomycin lung toxicity, especially with brentuximab or G-CSF PD-1 blockade + AVD chemotherapy

roadmaps

Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting

ideas

Chemotherapy-free Hodgkin lymphoma: brentuximab + PD-1 in early stage Measure the late effects of the treatments being given now, not the ones given in 1975

key papers

AHOD1331: brentuximab vedotin with chemotherapy in paediatric high-risk Hodgkin lymphoma Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk ECHELON-1: brentuximab vedotin replacing bleomycin in first-line chemotherapy for advanced Hodgkin lymphoma GHSG HD21: PET-guided BrECADD versus escalated BEACOPP in advanced-stage classical Hodgkin lymphoma PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group RATHL: adapted treatment guided by interim PET-CT in advanced Hodgkin lymphoma Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma SWOG S1826: nivolumab plus AVD chemotherapy versus brentuximab-AVD for advanced Hodgkin lymphoma in adolescents and adults

Notes

Advanced Hodgkin lymphoma, what the escalation decision costs and what it buys: This is orientation from public patient pages, guidelines and the trials themselves, not advice for your case: your own team's instructions and the 24-hour number they gave you come first, and no figure here is a prediction about you. The decision records, the question sets, the first 60 days checklist and the red cards on this page were written from the NHS, Lymphoma Action, Macmillan and Cancer Research UK patient pages, from NICE NG52, NG47, CG151 and NG234, from the NHS Breast Screening Programme protocols and the Green Book, and from the trial reports named beside each figure, all read on 1 October 2026.

Machine-readable versions

The same record for scripts and assistants; checked 2026-09-18. Data CC BY-NC 4.0, attribute “Data from OnCo (onco.cc)”.

JSON with neighbours Markdown context RDF Turtle Sections with routes and counts API root

Wikipedia

Hodgkin lymphoma

subtype-page haematologic

Make correction

Machine-readable versions of Advanced-stage classical Hodgkin lymphoma (stage III to IV)

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/cancers/advanced-stage-classical-hodgkin-lymphoma/)
Section plan: the ten sections of this record with routes, anchors and counts
All cancers as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id advanced-stage-classical-hodgkin-lymphoma.

WebMCP tools registered on this page: onco_search, onco_get_entity.